文献速递造血干细胞移植与细胞治疗

优化维生素D补充:口服薄膜胆钙化醇用于干细胞移植患者

Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant.
PubMed 文献 · Blood Adv · 2023-01-01

这项前瞻性先导研究纳入20例造血干细胞移植后血清维生素D≤35 ng/mL的患者,给予口服薄膜胆钙化醇12周,剂量按体重并依据个体药代动力学调整。中位基线维生素D从29.2 ng/mL升至研究结束时的58 ng/mL(P < .0001),所有患者第4周即有改善,中位剂量为每周1条(40 000 IU),未观察到毒性。

要点

  • 口服薄膜胆钙化醇12周使移植后难治性维生素D缺乏患者中位水平从29.2 ng/mL升至58 ng/mL(P < .0001)。
  • 所有20例患者第4周血清维生素D水平均有改善,中位剂量为每周1条(40 000 IU)。
  • 研究期间未观察到毒性,该制剂被评价为安全、有效、高效且接受度好。

核心结论

  • 口服薄膜胆钙化醇在造血干细胞移植后维生素D≤35 ng/mL的患者中安全有效,能使既往难治患者的血清维生素D水平显著提升。

研究设计与样本

  • 前瞻性先导研究,纳入20例造血干细胞移植后患者(入组时范围为移植后第+21天至第+428天),血清维生素D水平≤35 ng/mL。
  • 给予胆钙化醇口服薄膜12周,剂量基于患者体重并依据个体药代动力学调整。

主要发现

  • Wilcoxon配对符号秩检验显示全部20例既往难治患者维生素D水平显著改善,中位基线29.2 ng/mL升至研究结束时58 ng/mL(P < .0001)。
  • 所有患者在研究第4周血清维生素D水平即有改善,部分患者此前已难治多年。
  • 中位剂量为每周1条口服薄膜(40 000 IU),未观察到毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vitamin D deficiency is common in childhood, pervasive before and after bone marrow transplant, and is associated with increased incidence of graft-versus-host disease (GVHD) and decreased survival in patients undergoing hematopoietic stem cell transplant (HSCT). Numerous barriers impede replacement, including malabsorption secondary to gut GVHD, mucositis, inability to take capsules, kidney disease, liver disease, and infection; many patients remain refractory despite vitamin D therapy. We hypothesized that a different formulation of cholecalciferol, administered on the tongue as a readily dissolving oral thin film (OTF), would ease administration and facilitate therapeutic vitamin D levels (>35 ng/mL) in patients who are refractory. In this prospective pilot study, we evaluated 20 patients after HSCT (range, day +21 - day +428 at enrollment) with serum vitamin D levels ≤35 ng/mL. Cholecalciferol OTF strips were administered for 12 weeks. Dosing was based on patient body weight and titrated per individual pharmacokinetics. Wilcoxon matched-pairs signed-rank test demonstrated marked improvement in all 20 patients who were formerly refractory, increasing from a median baseline vitamin D level of 29.2 ng/mL to 58 ng/mL at end of study (P < .0001). All patients demonstrated improvement in serum vitamin D level by week 4 on study, some of whom had been refractory for years prior. Median dose was 1 OTF strip (40 000 IU) per week. No toxicity was observed. This formulation proved to be safe, effective, efficient, and well received. We are eager to explore other patient populations, which might benefit from this promising development, and other therapeutics that might be optimized using this mode of delivery. This trial was registered at www.clinicaltrials.gov as #NCT04818957.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bartlett AL, Zhang G, Wallace G, et al. Optimized vitamin D repletion with oral thin film cholecalciferol in patients undergoing stem cell transplant. Blood Adv. 2023. PMID: 37285801. doi:10.1182/bloodadvances.2023009855

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。